Free CME from PeerView


Gynecology/Obstetrics CME

Credits: 0.75 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care
June 23, 2022
Credits: 1.0 CME / MOC / CPE
Medical Learning Institute, Inc.
Making Sense of the Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy
May 06, 2022
Credits: 1.0 CME / MOC / CC / NCPD / CPE
Medical Learning Institute, Inc.
How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps
April 29, 2022
Credits: 1.5 NCPD / ILNA
PVI, PeerView Institute for Medical Education
Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies
April 28, 2022
Credits: 0.5 CME / MOC / NCPD
Medical Learning Institute, Inc.
Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
April 27, 2022
Credits: 1.5 CME / MOC / CC
PVI, PeerView Institute for Medical Education
Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
April 10, 2022
Credits: 1.25 CME
Medical Learning Institute, Inc.
Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier Settings
April 08, 2022
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations
April 01, 2022
Credits: 0.5 CME
Medical Learning Institute, Inc.
Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm
March 31, 2022
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
March 23, 2022
Credits: 1.0 CME / MOC / NCPD
Medical Learning Institute, Inc.
When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
March 22, 2022
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
March 12, 2022
Credits: 0.5 CME
PVI, PeerView Institute for Medical Education
Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It?
February 25, 2022
Credits: 0.5 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies
November 30, 2021
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
PrEP for All Ages: A Comprehensive Look at Employing HIV Prevention Strategies Across All Age Groups
November 18, 2021
Donna E. Sweet, MD, AAHIVS, MACP
Credits: 0.75 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The HIV Prevention–Certified Provider Program: A Training and Certificate Program Designed to Improve Competencies and Expand the HIV Prevention Workforce
November 12, 2021
Credits: 1.0 CME / MOC / CC / NCPD / CPE
Medical Learning Institute, Inc.
Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors
November 08, 2021
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
September 29, 2021
Medical Learning Institute, Inc.
Target Practice: Understanding How PARP Inhibitors Take Aim at DNA Damage Response Mutations Across Solid Tumors
May 07, 2021

Pages